{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:15:30Z","timestamp":1793949330080,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL128526"],"award-info":[{"award-number":["R01 HL128526"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL162828"],"award-info":[{"award-number":["R01 HL162828"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01 HL160226"],"award-info":[{"award-number":["U01 HL160226"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23HL164901"],"award-info":[{"award-number":["K23HL164901"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41591-024-03140-1","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T06:01:53Z","timestamp":1720764113000},"page":"2258-2264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score"],"prefix":"10.1038","volume":"30","author":[{"given":"Yogesh N. V.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-273X","authenticated-orcid":false,"given":"Rickey E.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-0372","authenticated-orcid":false,"given":"David M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-7865","authenticated-orcid":false,"given":"M. Louis","family":"Handoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-7722","authenticated-orcid":false,"given":"Ryan J.","family":"Tedford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-8227","authenticated-orcid":false,"given":"Mads J.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Obokata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0599-9290","authenticated-orcid":false,"given":"Frederik H.","family":"Verbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-0596","authenticated-orcid":false,"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"3140_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jchf.2020.03.013","volume":"8","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj, S. et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. JACC Heart Fail. 8, 640\u2013653 (2020).","journal-title":"JACC Heart Fail."},{"key":"3140_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug, B. A., Sharma, K., Shah, S. J. & Ho, J. E. Heart failure with preserved ejection fraction: JACC scientific statement. J. Am. Coll. Cardiol. 81, 1810\u20131834 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3140_CR3","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/eurheartj\/ehad141","volume":"44","author":"J Verwerft","year":"2023","unstructured":"Verwerft, J. et al. Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic. Eur. Heart J. 44, 1544\u20131556 (2023).","journal-title":"Eur. Heart J."},{"key":"3140_CR4","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/eurjpc\/zwad127","volume":"30","author":"Y Saito","year":"2023","unstructured":"Saito, Y. et al. Prognostic benefit of early diagnosis with exercise stress testing in heart failure with preserved ejection fraction. Eur. J. Prev. Cardiol. 30, 902\u2013911 (2023).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"3140_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3140_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3140_CR7","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","volume":"29","author":"BA Borlaug","year":"2023","unstructured":"Borlaug, B. A. et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat. Med. 29, 2358\u20132365 (2023).","journal-title":"Nat. Med."},{"key":"3140_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3140_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy, Y. N. V., Carter, R. E., Obokata, M., Redfield, M. M. & Borlaug, B. A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138, 861\u2013870 (2018).","journal-title":"Circulation"},{"key":"3140_CR10","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske, B. et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 40, 3297\u20133317 (2019).","journal-title":"Eur. Heart J."},{"key":"3140_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","volume":"7","author":"YNV Reddy","year":"2022","unstructured":"Reddy, Y. N. V. et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol. 7, 891\u2013899 (2022).","journal-title":"JAMA Cardiol."},{"key":"3140_CR12","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1093\/eurheartj\/ehy268","volume":"39","author":"M Obokata","year":"2018","unstructured":"Obokata, M. et al. Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. Eur. Heart J. 39, 2810\u20132821 (2018).","journal-title":"Eur. Heart J."},{"key":"3140_CR13","doi-asserted-by":"publisher","first-page":"e195321","DOI":"10.1001\/jamanetworkopen.2019.5321","volume":"2","author":"SHR Ramalho","year":"2019","unstructured":"Ramalho, S. H. R. et al. Association of undifferentiated dyspnea in late life with cardiovascular and noncardiovascular dysfunction: a cross-sectional analysis from the ARIC study. JAMA Netw. Open 2, e195321 (2019).","journal-title":"JAMA Netw. Open"},{"key":"3140_CR14","volume":"42","author":"RMJ van der Velden","year":"2022","unstructured":"van der Velden, R. M. J. et al. Dyspnea in patients with atrial fibrillation: mechanisms, assessment and an interdisciplinary and integrated care approach. Int. J. Cardiol. Heart Vasc. 42, 101086 (2022).","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"3140_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/archinte.162.13.1477","volume":"162","author":"DD Sin","year":"2002","unstructured":"Sin, D. D., Jones, R. L. & Man, S. F. P. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch. Intern. Med. 162, 1477\u20131481 (2002).","journal-title":"Arch. Intern. Med."},{"key":"3140_CR16","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J. Am. Coll. Cardiol. 79, e263\u2013e421 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3140_CR17","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif, M. E. et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat. Med. 27, 1954\u20131960 (2021).","journal-title":"Nat. Med."},{"key":"3140_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3140_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3140_CR20","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato, E. T. et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139, 2528\u20132536 (2019).","journal-title":"Circulation"},{"key":"3140_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3140_CR22","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3140_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s44161-021-00005-5","volume":"1","author":"KE Koepp","year":"2022","unstructured":"Koepp, K. E. et al. Identification of patients with preclinical heart failure with preserved ejection fraction using the H2FPEF score. Nat. Cardiovasc. Res. 1, 59\u201366 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"3140_CR24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cardfail.2020.08.008","volume":"26","author":"YNV Reddy","year":"2020","unstructured":"Reddy, Y. N. V. et al. Characterization of the progression from ambulatory to hospitalized heart failure with preserved ejection fraction. J. Card. Fail. 26, 919\u2013928 (2020).","journal-title":"J. Card. Fail."},{"key":"3140_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2014.03.014","volume":"2","author":"P Wohlfahrt","year":"2014","unstructured":"Wohlfahrt, P. et al. Impact of general and central adiposity on ventricular-arterial aging in women and men. JACC Heart Fail. 2, 489\u2013499 (2014).","journal-title":"JACC Heart Fail."},{"key":"3140_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman, D. W. et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315, 36\u201346 (2016).","journal-title":"JAMA"},{"key":"3140_CR27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2019.04.019","volume":"7","author":"YNV Reddy","year":"2019","unstructured":"Reddy, Y. N. V. et al. Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. JACC Heart Fail. 7, 678\u2013687 (2019).","journal-title":"JACC Heart Fail."},{"key":"3140_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","volume":"141","author":"SJ Shah","year":"2020","unstructured":"Shah, S. J. et al. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute working group summary. Circulation 141, 1001\u20131026 (2020).","journal-title":"Circulation"},{"key":"3140_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/ejhf.2142","volume":"23","author":"FH Verbrugge","year":"2021","unstructured":"Verbrugge, F. H. et al. Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction. Eur. J. Heart Fail. 23, 954\u2013963 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"3140_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ejhf.2747","volume":"25","author":"K Omote","year":"2023","unstructured":"Omote, K. et al. Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. Eur. J. Heart Fail. 25, 185\u2013196 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"3140_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/CIRCULATIONAHA.117.030093","volume":"137","author":"YNV Reddy","year":"2018","unstructured":"Reddy, Y. N. V., Obokata, M., Gersh, B. J. & Borlaug, B. A. High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea. Circulation 137, 534\u2013535 (2018).","journal-title":"Circulation"},{"key":"3140_CR32","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","volume":"76","author":"YNV Reddy","year":"2020","unstructured":"Reddy, Y. N. V., Obokata, M., Verbrugge, F. H., Lin, G. & Borlaug, B. A. Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J. Am. Coll. Cardiol. 76, 1051\u20131064 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3140_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12872-018-0866-5","volume":"18","author":"YR Patel","year":"2018","unstructured":"Patel, Y. R. et al. Development and validation of a heart failure with preserved ejection fraction cohort using electronic medical records. BMC Cardiovasc. Disord. 18, 128 (2018).","journal-title":"BMC Cardiovasc. Disord."},{"key":"3140_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven, D. J. & B\u00fchlmann, P. MissForest\u2014non-parametric missing value imputation for mixed-type data. Bioinformatics 28, 112\u2013118 (2012).","journal-title":"Bioinformatics"},{"key":"3140_CR35","doi-asserted-by":"publisher","unstructured":"Reddy, Y. N. V. & Borlaug, B. A. HFpEF ABA derivation and validation data and code. Figshare https:\/\/doi.org\/10.6084\/m9.figshare.26020810.v1 (2024).","DOI":"10.6084\/m9.figshare.26020810.v1"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03140-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:13:06Z","timestamp":1724047986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03140-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3140"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03140-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.A.B. receives research support from the NIH and the US Department of Defense, as well as research grant funding from AstraZeneca, Axon, GSK, Medtronic, Mesoblast, Novo Nordisk and Tenax Therapeutics. He has served as a consultant for Actelion, Amgen, Aria, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Janssen, Merck and Novo Nordisk. B.A.B. and S.J.A. are named inventors (US patent no. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Y.N.V.R. receives research support from the NIH, Sleep Number, Bayer, Merck and United Pharmaceuticals. M.L.H. reported receiving grants from the Dutch Heart Foundation and educational, speaker and consultancy fees from Novartis, Boehringer Ingelheim, AstraZeneca, Vifor Pharma, Bayer, Merck, Abbott, Daiichi Sankyo and Quin outside the submitted work. R.J.T. reports no direct conflicts of interest related to this manuscript. He is co-chair of the Pulmonary Hypertension due to Left Heart Disease Task Force for the 7th World Symposium on Pulmonary Hypertension. He reports general disclosures that include consulting relationships with Abbott, Acorai, Aria CV, Acceleron\/Merck, Alleviant, CareDx, Cytokinetics, Edwards LifeSciences, Gradient, Lexicon Pharmaceuticals, Medtronic and United Therapeutics. R.J.T. serves on the steering committees for Merck, Edwards and Abbott, as well as a research advisory board member for Abiomed. He also does hemodynamic core laboratory work for Merck. M.J.A. reports no direct conflicts of interest related to this manuscript. He reports a consulting relationship with Johnson & Johnson. F.H.V. reports no direct conflicts of interest related to this manuscript. He reports a consulting relationship with Abbott Laboratories, Abiomed, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb Belgium, Daiichi Sankyo, Menarini Benelux, MSD, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics and Qompium. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}